Trump Unveils Phased Tariff Plan on Imported Generic Drugs to Force Reshoring

In a bid to force pharmaceutical companies to relocate their manufacturing operations to the United States, President Donald Trump has announced a phased tariff structure targeting imported generic medicines. The plan offers drugmakers a two-year grace period before imposing punitive duties that will eventually reach 200%.

Under the newly outlined policy, all imported generic drugs will maintain a 0% tariff rate for a two-year transition period starting August 1, 2026. Once this window closes in mid-2028, the import tax will climb to 100% for one year, before permanently doubling to 200% thereafter. The administration stated that the policy for patented, branded, and innovative pharmaceuticals will remain unchanged.

The aggressive timeline is designed to give pharmaceutical companies a clear runway to establish domestic manufacturing facilities. In a statement on social media, Trump framed the measures as a necessary step to protect national security and reduce America’s reliance on foreign supply chains for critical healthcare needs, warning of steep financial penalties for companies that choose not to build domestic plants.

The policy targets a highly sensitive sector of the American healthcare system. According to the U.S. Food and Drug Administration, generic drugs account for more than 90% of all prescriptions filled in the United States. However, the vast majority of these medications, along with the active pharmaceutical ingredients required to make them, are manufactured abroad—primarily in India and China.

This heavy reliance on global supply chains has long been flagged by public health experts as a vulnerability. Disruptions during the COVID-19 pandemic and ongoing quality control issues at overseas plants have frequently led to critical shortages of basic life-saving medications in U.S. hospitals. While successive administrations have sought to address these vulnerabilities, the proposed tariff escalation represents the most disruptive policy intervention to date.

The generic pharmaceutical industry has reacted with caution, highlighting the complex economics of drug manufacturing. John Murphy III, the president and CEO of the Association for Accessible Medicines, stated that while the industry supports efforts to stabilize and secure supply chains, more details are needed to understand the full impact of the tariff proposal.

Murphy noted that while domestic investments have increased over the last two years, deep-seated structural issues in the U.S. market—particularly regarding purchasing consolidation and low reimbursement rates—continue to act as major barriers to expanding domestic manufacturing. Generic drug production operates on razor-thin profit margins, and industry analysts warn that sudden, steep tariffs could lead to higher prices for consumers or cause some manufacturers to pull out of the U.S. market entirely, potentially worsening drug shortages.

By delaying the implementation of the first tariff hike until 2028, the administration is giving the pharmaceutical sector a tight window to overhaul supply chains that have taken decades to build. Whether the industry can successfully build the necessary infrastructure in the U.S. within that timeframe remains a critical question for healthcare providers and patients alike.